Nexalis Therapeutics Ltd Overview
Nexalis Therapeutics is a Melbourne-based, micro-capitalisation, clinical-stage drug developer whose corporate shell traces back to Lifespot Health, a medical diagnostics and remote-monitoring company that pivoted into medicinal cannabis inhalation devices in 2020–2021 and then into regulated drug development. The company now pursues US FDA approval of three reformulated, previously approved molecules via the 505(b)(2) pathway: IRX-211 (inhaled synthetic THC/dronabinol in a pressurised metered-dose inhaler) for breakthrough cancer pain; IRX-616a (inhaled cannabidiol) for acute panic disorder; and SRX-25 (oral esketamine plus a CYP450 inhibitor) for treatment-resistant depression. Its strategic logic is capital-light reformulation of known actives with rapid onset and better access. However, as of October 2026 the company is in acute financial distress: its A$52.3M debt facility was cancelled in May 2026, a replacement facility collapsed in July 2026, clinical work is suspended, it carries net liabilities of A$1.86M, and its auditor has flagged material going-concern uncertainty.
Company's own description
In its latest filings (Half-Year Report to 30 June 2026; ASX boilerplate from 2026 announcements), the company describes itself as an Australian clinical-stage drug development company developing rapid-onset therapies for unmet needs in pain management and mental health, with an overarching goal of US FDA approval via cost-effective regulatory pathways such as 505(b)(2). The stated principal activity in the 1H2026 Directors' Report is the development of registrable inhaled drugs intended to give fast relief to sufferers of pain and anxiety-related illnesses. The February 2026 rebrand was explained as reflecting a shift beyond inhaled therapies following the addition of the SRX-25 oral program, positioning the company as a diversified clinical-stage developer.
Independent characterisation
Nexalis is a pre-revenue, single-segment, virtual biotech. It owns no manufacturing, no laboratories and has negligible fixed assets (property, plant and equipment of A$12,677 at 30 June 2026). Its value chain position is the "asset sponsor" layer: it holds intellectual property (method-of-use and device-enabled delivery claims, plus a filed international patent application) and contracts out formulation, manufacturing, trial management and site work. The principal outsourced partner is iNGENū CRO Pty Ltd, an entity related to CEO and Executive Director Darryl Davies, which accounted for A$906,712 of the A$1,275,757 product development expenditure in 1H2026 and is owed A$2,125,952 at 30 June 2026.
Business model and revenue model
| Revenue category | Current contribution | Notes |
|---|---|---|
| Product sales | Nil since FY2022 | Historic Medihale device/pod sales: A$167,301 in FY2021; minimal in FY2022; discontinued thereafter |
| Services | Nil | Historic BodyTel telehealth/remote-monitoring services pre-2021 |
| Subscription | Nil | Medihale was supplied to patients via clinic prescriptions under the TGA Special Access Scheme (2021) |
| Licensing / royalties | Nil to date | Intended future model: partner or out-license Phase 3-ready assets |
| Government incentives | Principal "income" | R&D Tax Incentive refundable offset: A$761,958 recognised FY2025 (prelim; ~A$986k post-audit, see Section 6), A$630,103 in 1H2026 |
The intended monetisation route, as stated in funding announcements, is to reach "Phase 3-ready" status for each asset and then realise value through partnering, licensing or trade sale, with lender options structured to vest in tranches when each program becomes Phase 3 ready.
Customer types and end-markets
| End-market | Target patients | Prescriber / payer channel (intended) |
|---|---|---|
| Breakthrough cancer pain (BTcP) | Opioid-tolerant cancer patients with episodic pain flares | Oncology and palliative care; US/EU/AU payers |
| Panic disorder (PD) | Patients experiencing acute panic and anxiety episodes | Psychiatry, primary care |
| Treatment-resistant depression (TRD) | Adults failing two or more antidepressants | Psychiatry; aims for home dosing vs clinic-supervised Spravato |
Strategy
Stated strategy (themes from FY2025/1H2026 filings and Feb 2026 Clinical Development Outlook)
-
Pursue New Drug Approvals with the US FDA as quickly and cost-effectively as possible using the 505(b)(2) pathway, leveraging existing safety data for known molecules.
-
Target indications where current options are mismatched or carry dependency concerns (fentanyl-based BTcP products; benzodiazepines for panic; supervised intranasal esketamine for TRD).
-
Use non-dilutive, clinical-trial-specific debt funding (with option-based upside to lenders vesting at Phase 3 readiness) instead of equity.
-
Develop assets to Phase 3 readiness and then partner.
-
Disciplined capital allocation and efficient trial execution (Mar 2026 quarterly).
Initiatives in the last 24 months
| Initiative | Date | Detail | Outcome |
|---|---|---|---|
| Clendon Biotech Capital facility | Oct 2024 | Up to A$38.5M, 15% interest capitalised, options ~19.9% of shares | Succeeded by LFO facility |
| Expansion of trial scope | Late 2024–2025 | Lender encouraged larger trial scale to support Phase 3 readiness | Increased cost base |
| iNGENū CRO appointment | Mar 2025 | Tendered CRO for IRX-211 and IRX-616a | Study orders suspended May/Jun 2026 |
| SRX-25 addition | Nov 2025 | Oral esketamine + CYP450 inhibitor for TRD | Protocol drafted; unfunded |
| LFO facility expansion | Dec 2025 | +A$12.6M; total ~A$52.3M | Cancelled 20 May 2026 |
| Rebrand to Nexalis | Feb 2026 | Reflects broadened modality focus | Completed |
| Point8 Capital facility | May 2026 | Binding LOI for up to A$53M in three sub-facilities, 15% interest, general security deed | Ceased 6 Jul 2026 |
| Cost-saving program | 2,026 | Product development activities ceased; discretionary spend reduced | Ongoing |
| Revised clinical development plan | Jul 2026 onward | Reprioritisation across three assets; IRX-211 recruitment review; IRX-616a Phase 2 design | Under way |
ESG/sustainability commitments: none disclosed.
Medium-term targets / guidance
No financial guidance has been issued. Earlier operational targets (e.g., IRX-211 first patient first dose in Q3 2025; SRX-25 first patient screened Q4 2025) were missed or superseded. As of October 2026 the company states it has no meaningful funding discussions under way.
Products & Services
Current development pipeline
IRX-211 (Breakthrough Cancer Pain)
-
Description: Drug-device combination delivering a fixed dose of dronabinol (synthetic THC) via pressurised metered-dose inhaler (pMDI), designed for rapid onset and offset analgesia during acute pain flares.
-
Target customer: Opioid-tolerant cancer patients with BTcP, positioned as an alternative to rapid-onset fentanyl products that carry dependency risk.
-
Development: Phase 1 single-ascending-dose study (four cohorts of eight healthy volunteers) completed 2023; final CSR 2024 confirmed safety and identified Phase 2 dose (1H2024 report). Phase 2 is a multicentre, randomised, double-blind, placebo-controlled crossover study with individual dose titration targeting 156 participants (ASX 20 Apr 2026; 1H2026 report). Lead site Vitalis (Melbourne); GenesisCare sites budget agreed Dec 2025.
-
Regulatory: 505(b)(2) pathway; company expects three-year data exclusivity on approval (Stockhead interview).
-
Pricing: Not disclosed.
IRX-616a (Panic Disorder)
-
Description: Inhaled cannabidiol formulation in a pMDI for rapid systemic absorption to treat acute panic and anxiety episodes.
-
Development: Phase 1 randomised, double-blind, placebo-controlled study in up to 24 healthy volunteers at CMAX Adelaide; cohort 1 (8 subjects) completed by 17 Apr 2026; SRC approved cohort 3 on 28 Apr 2026; completed during 1H2026 with no serious adverse events (ASX 6 Jul 2026).
-
Market gap claim: Company states there is no FDA-approved inhaled drug for panic disorder.
-
Pricing: Not disclosed.
SRX-25 (Treatment-Resistant Depression)
-
Description: Oral fixed-dose combination of esketamine with a CYP450 inhibitor intended to reduce first-pass metabolism and improve systemic exposure, enabling oral, potentially home-based dosing versus J&J's clinic-supervised intranasal Spravato (ASX 26 Nov and 4 Dec 2025).
-
Development: Phase 1 protocol and Investigator's Brochure drafted (Q1 2026); IP strategy progressed; Phase 1 planned for Australia once funded (1H2026 report).
-
Pricing: Not disclosed.
Discontinued / legacy products
| Product | Era | Description | Status |
|---|---|---|---|
| Medihale inhaler and pods | 2020–2022 | Sealed, tamper-resistant pod vaporiser for medical cannabis c-liquids (heat-not-burn); pods filled with EC Pharma formulations (e.g., 275mg CBD/275mg THC); prescribed via TGA SAS | Generated A$167,301 revenue FY2021; de-emphasised as company moved to registrable drugs |
| BodyTel system | 2016–2020 | Chronic-disease and remote-monitoring telehealth platform (glucose, blood pressure, etc.) | Legacy; disposal details not disclosed in reviewed sources |
| Omnitest 5 BT (with B. Braun) | 2,018 | Bluetooth glucose meter integrated with Body-Tel | Legacy partnership |
| FeverTel | 2,020 | Temperature-monitoring extension of BodyTel during COVID-19 | Legacy |
| Coagulation home monitoring | 2,017 | Announced market entry | Legacy |
| IRX211 for CRPS | 2022–2023 | Original lead indication | Replaced by BTcP (Jan 2024) |
Financial Narrative
Data provenance: FY2021–FY2023 from annual reports as reported by StockAnalysis/TipRanks/Kalkine and cross-checked against FY2022 Annual Report and FY2024 4E comparatives; FY2024 from FY2024 Annual Report/FY2025 4E comparatives; FY2025 from unaudited Appendix 4E (27 Feb 2026) unless marked audited (derived from 1H2026 comparatives).
Income statement
Notes:
-
FY2022 revenue conflicts across aggregators (A$24.8k TipRanks; A$0.02M StockAnalysis; A$52k Stockopedia). A$25k used.
-
FY2021–FY2023 EPS computed from net loss / weighted shares (167.57M, 173.05M, 189.38M per TipRanks); FY2024–FY2025 EPS as reported.
-
FY2024 EBITDA approximated as pre-tax loss less finance costs (aggregators conflict); FY2025 EBITDA approximated similarly from 4E.
-
Margins: gross, operating, EBITDA and net margins are not meaningful given nil customer revenue from FY2023. FY2021 net margin on sales was approx. -664%.
-
Revenue CAGR FY2021–FY2025: not meaningful (revenue fell to zero).
Balance sheet
Notes: FY2025 total assets, equity and working capital shown on the audited basis (1H2026 comparatives: total assets A$1,432,620; equity -A$950,524). Unaudited 4E showed total assets A$1,208,144 and equity -A$1,175,000. FY2021–FY2022 debt assumed nil (no borrowings evident; convertible notes first appear in FY2024 cash flows). Blank cells = not publicly disclosed in reviewed sources.
30 June 2026 snapshot (Half-Year Report): cash A$791,334; receivables A$729,537 (R&D rebate A$630,103); total assets A$1,625,036; trade and other payables A$2,762,512 (of which A$2,125,952 owed to related party iNGENū); borrowings A$720,084 (LFO facility A$641,848, insurance funding A$78,236); total liabilities A$3,489,218; net liabilities A$1,864,182; current liabilities exceed current assets by A$1,875,337.
Cash flow: notes and sources
Notes: FY2021–FY2023 operating and financing flows per Kalkine aggregation (FY2021–FY2022 operating cash flow inferred from free cash flow, capex nil). FY2025 financing comprised A$535k share proceeds, A$1,022k borrowings, less A$369k repayments and A$58k costs.
Commentary
The five-year record is that of a shell in transition rather than an operating business. FY2021 was the last year with product revenue (Medihale), and the A$2.8M cash balance at end-FY2021 was the high-water mark following the 2020 Cannvalate and MDI placements. From FY2022 the company redirected spend to clinical development; R&D expense rose to A$0.98M in FY2022 and A$1.45M in FY2023 as the IRX211 Phase 1 ran, cash fell to A$0.72M by end-FY2023, and FY2024 was a holding year (R&D just A$0.62M) while the company negotiated the Clendon facility. FY2025 saw R&D nearly triple to A$1.76M as Phase 2 and Phase 1 trial drug manufacturing proceeded, financed by a mix of the lender facility, R&D financing and a small equity raise.
The key inflection is the balance sheet: equity turned negative in FY2024 (-A$64k) and deteriorated to -A$951k (audited) at end-FY2025 and -A$1.86M at 30 June 2026, primarily because trial costs were being incurred on credit from the related-party CRO (trade payables up from A$568k at end-FY2024 to A$2.44M at 30 June 2026) in anticipation of lender drawdowns that never arrived. Of A$2.4M in drawdown requests submitted to LFO, only A$0.8M was received before cancellation. The R&D Tax Incentive (43.5% refundable offset for small entities) is now the company's most reliable inflow and is explicitly a key input to the going-concern forecast.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Single segment revenue from customers (AUD K) | 0 | 0 | 0 |
Single segment other income incl. R&D rebate (AUD K) | 1,200 | 560 | 768 |
Single segment pre-tax loss (AUD K) | -1,443 | -1,209 | -1,829 |
Capital Programmes
| Program | Modality | Indication | Stage (Oct 2026) | Status |
|---|---|---|---|---|
IRX-211 | Inhaled dronabinol (synthetic THC), pMDI | Breakthrough cancer pain | Phase 2 (first patient screened Apr 2026) | Study order with iNGENū suspended; recruitment review under way |
IRX-616a | Inhaled cannabidiol (CBD), pMDI | Panic disorder | Phase 1 complete (healthy volunteers) | Database lock and CSR delayed; Phase 2 design in progress |
SRX-25 | Oral esketamine + CYP450 inhibitor, fixed-dose | Treatment-resistant depression | Pre-clinical / Phase 1 protocol drafted | Awaiting funding |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue from customers (AUD K) | 167 | 25 | 0 | 0 | 0 |
Other income incl. R&D rebate (AUD K) | 0 | 0 | 1,200 | 560 | 768 |
Product development / R&D expense (AUD K) | 120 | 980 | 1,450 | 622 | 1,760 |
SG&A and corporate expenses (AUD K) | 990 | 890 | 1,080 | 1,020 | 670 |
Operating income (AUD K) | -1,110 | -1,950 | -1,420 | -1,280 | -1,490 |
EBITDA (AUD K) | -1,120 | -1,940 | -1,410 | -1,200 | -1,690 |
Finance costs (AUD K) | 0 | 0 | 10 | 88 | 136 |
Pre-tax income (AUD K) | -1,111 | -1,927 | -1,443 | -1,209 | -1,829 |
Net income (AUD K) | -1,111 | -1,927 | -1,443 | -1,209 | -1,829 |
Basic EPS (A$ cents) | -0.66 | -1.11 | -0.76 | -0.567 | -0.848 |
Diluted EPS (A$ cents) | -0.66 | -1.11 | -0.76 | -0.567 | -0.848 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Income Statement (AUD) and Per-Share Data
| Metric (AUD) | 1H2025 | 1H2026 | Change |
|---|---|---|---|
Other income (R&D rebate) | 551,449 | 630,103 | +14.3% |
Product development expenditure | 1,006,114 | 1,275,757 | +26.8% |
Directors' fees | 1,270 | 108,988 | — |
Finance costs | 55,115 | 121,543 | +120.5% |
Net loss | 854,332 | 1,297,938 | +51.9% |
Basic EPS (cents) | -0.40 | -0.52 | — |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash and equivalents (AUD K) | 2,803 | 2,133 | 716 | 195 | 437 |
Total assets (AUD K) | — | — | — | 712 | 1,433 |
Total liabilities (AUD K) | — | — | — | 776 | 2,383 |
Short-term debt (AUD K) | — | — | — | 34 | 426 |
Long-term debt (AUD K) | — | — | — | 0 | 315 |
Total debt (AUD K) | — | — | — | 34 | 741 |
Net debt (AUD K) | -2,803 | -2,133 | -716 | -161 | 304 |
Total equity (AUD K) | — | — | 665 | -64 | -951 |
Goodwill and intangibles (AUD K) | — | — | 0 | 0 | 0 |
Working capital (AUD K) | — | — | — | -64 | -634 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -1,174 | -1,846 | -1,962 | -369 | -888 |
Capex (AUD K) | 0 | 0 | 0 | 0 | 0 |
Free cash flow (AUD K) | -1,174 | -1,846 | -1,962 | -369 | -888 |
Financing cash flow (AUD K) | 2,258 | 1,176 | 544 | -152 | 1,130 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
R&D tax offset received (AUD K) | — | — | — | 763 | 490 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | 1H2026 |
|---|---|---|---|---|
ROE | — | n.m. (negative equity) | — | — |
ROA (net loss / total assets) | — | -170% | -113% (audited basis) | n.m. (half-year) |
Current ratio | — | 0.92x | 0.69x | 0.46x |
Asset turnover | 0 | 0 | 0 | 0 |
“—” = not publicly disclosed.
Results by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Australia revenue from customers (AUD K) | 0 | 0 | 0 |
Rest of world revenue from customers (AUD K) | 0 | 0 | 0 |
Australia R&D rebate income (AUD K) | 1,200 | 402 | 762 |
Share Price
| Metric | 2021 | 2025 | 2026 |
|---|---|---|---|
Reference share price (AUD) | 0.095 | 0.025 | 0.011 |
Performance Details
| Performance | Value | Source |
|---|---|---|
1-year (relative to ASX 200) | -78.5% | Market Index |
~1-year absolute (from ~A$0.036 on 26 Nov 2025 to ~A$0.011) | approx. -70% | InvestSMART price at release |
~5-year absolute (A$0.095 Oct 2021 to ~A$0.011) | approx. -88% | Computed |
Long-run (from A$0.31–0.33 in early 2017) | approx. -97% | Computed from InvestSMART release prices |
52-week range | approx. A$0.009 – A$0.036 | InvestSMART / Kalkine |
ASX rank by market cap | 2,288 of 2,337 | Market Index |
Valuation Snapshot
| Multiple | Value |
|---|---|
P/E | n.m. (loss-making) |
EV/Sales | n.m. (MarketScreener shows ~6x on R&D rebate "sales"; not meaningful) |
P/B | n.m. (negative book value) |
Approx. EV | Market cap ~A$2.7M + borrowings A$0.08M (post-settlement) - cash A$0.79M ≈ A$2.0M, excluding A$2.76M trade payables |
Analyst Conclusions
Management guidance
No financial guidance. Management states its focus is identifying funding options, establishing clinical development priorities and planning capital-efficient execution (Jun-26 quarterly), while seeking deferral of most of the A$2.13M owed to iNGENū until a significant capital raise or new funding partner is secured. Consensus growth expectations: none (no coverage).
Bull case
-
Optionality at a near-zero valuation: Two Phase 1-complete inhaled assets and an esketamine program trade at an EV of roughly A$2M; any licence or funding partner could re-rate the stock several-fold.
-
IRX-616a de-risked on safety: Clean Phase 1 with dose-ranging insights in an indication without an approved inhaled therapy makes it the most partnerable asset.
-
Clean-up of liabilities: The LFO settlement removed secured debt and 38.4M options; the R&D rebate (A$630k receivable) provides near-term cash.
Bear case
-
Funding cliff: Two consecutive facility failures and no active negotiations, with liabilities exceeding A$3.4M against under A$0.8M cash at 30 June 2026.
-
Execution doubts: IRX-211 Phase 2 struggled to recruit even when funded, and the company added a third program it could not finance.
-
Governance and related-party concentration: The CEO-related CRO is both the main supplier and largest creditor, complicating independent decision-making and any restructuring.
Key catalysts and monitorables (next 12 months)
-
Sep-26 quarterly Appendix 4C (due by 31 Oct 2026): cash balance and any iNGENū deferral agreement.
-
Receipt of the A$630k R&D rebate receivable.
-
Any new funding facility, equity raise, partnering or asset sale announcement.
-
Completion of IRX-616a database lock and Clinical Study Report.
-
Outcome of IRX-211 Phase 2 recruitment review and revised clinical plan.
-
FY2026 audited accounts (Feb–Mar 2027) and going-concern opinion.
-
Board strengthening (independent directors) and any ASX queries on financial condition.
Analyst verdict
Lifespot Health has undergone two complete reinventions since listing in 2017: from remote health monitoring (BodyTel) to medicinal cannabis devices (Medihale), and then to regulated drug development as InhaleRx and now Nexalis Therapeutics. The current strategy is intellectually coherent. Reformulating known actives such as dronabinol, CBD and esketamine for faster onset or better access, and seeking FDA approval through the 505(b)(2) pathway, is a recognised, capital-efficient biotech playbook. Clinically, the company has delivered: two Phase 1 studies completed without serious safety signals, and a Phase 2 trial initiated.
Financially, however, the business is in survival mode. The model depended entirely on a single lender advancing clinical funding against invoices; when Linlithgow cancelled in May 2026 after funding only A$0.8M of A$2.4M requested, and Point8's replacement collapsed in July, the company was left with suspended trials, net liabilities of A$1.86M, and A$2.13M owed to a CRO related to its own CEO. Its auditor has flagged material going-concern uncertainty, and management has acknowledged that no meaningful funding talks are under way. At roughly A$0.011 per share and a market capitalisation near A$3M, the equity is priced as an option on a rescue transaction rather than on the science.
Our assessment is that the probability-weighted outcome is dominated by recapitalisation terms: a successful partnering of IRX-616a or a deeply discounted raise could preserve the assets, but existing shareholders should expect heavy dilution in nearly every survival scenario, and a creditor-driven restructuring cannot be excluded. Governance improvements, in particular independent board additions and an arm's-length resolution of the iNGENū exposure, are prerequisites for institutional capital. Until funding is secured, the stock is suitable only for speculative, loss-tolerant capital, and the key near-term test is the September-quarter cash report and any announced funding solution.
All items marked "not publicly disclosed" should be verified against the 2025 Annual Report lodged 31 March 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background (public) | Independence |
|---|---|---|---|---|
Sean Williams | Non-Executive Chairman | Oct 2021 | Appointed chair at the InhaleRx rebrand; fees taken in share rights (Jul 2026) | Treated as independent NED (not formally confirmed in reviewed sources) |
Darryl Davies | CEO and Executive Director | CEO since 27 Sep 2022; Director since 25 Jun 2026 | B.Sc.; related to iNGENū CRO Pty Ltd, the company's principal CRO and largest creditor | Not independent |
James Barrie | Non-Executive Director and Company Secretary | Director since 12 May 2026 | CPA; long-standing company secretary; received A$7,500 for secretarial services in 1H2026 | Not independent (executive service provider) |
Executive Leadership Team
| Name | Title | Tenure |
|---|---|---|
Darryl Davies | Chief Executive Officer | Since Sep 2022 |
Dr Robert (Rob) Jenny, B.A., B.Sc., Ph.D. | Chief Scientific / Technology Officer | Since Sep 2022 |
Greg Hammond | Chief Financial Officer | — |
James Barrie, CPA | Company Secretary | Multi-year |
“—” = not publicly disclosed.
Directors' Remuneration
| Item | Amount (AUD) | Source |
|---|---|---|
Shares issued to settle CEO fees, Oct 2025 | 149,850 (4,499,914 shares at A$0.0333) | FY2025 4E Note 7 |
Shares issued to settle CEO fees, Oct 2024 | 99,900 (3,444,828 shares) | FY2025 4E Note 7 |
Shares issued to settle directors' fees, Dec 2024 | 75,890 | FY2025 4E Note 7 |
Directors' fees expense FY2025 (cash, prelim) | 1,270 | FY2025 4E |
Directors' fees expense 1H2026 | 108,988 | 1H2026 report |
Fees payable to KMP at 30 Jun 2026 | 194,789 | 1H2026 Note 11 |
Performance/share rights to current and former directors, 14 Jul 2026 | 4,120,019 rights | 1H2026 Note 12 |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Citicorp Nominees Pty Ltd | 1.70% (3,623,477 shares) | Market Index (date of compilation unclear) |
HSBC Custody Nominees (Australia) | 1.31% (2,799,928 shares) | Market Index |
Cannvalate Pty Ltd (historic) | 17.92% (30.2M shares) | Mar 2021 |
M I D Wealth Pty Ltd (historic) | 7.78% (13.1M shares) | Mar 2021 |
Pyxis Holdings Pty Ltd (historic) | 5.29% | Mar 2021 |
Unnamed substantial holder change | — | ASX notice 30 Jul 2026 |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Program | Competitor / product | Company | Type | Positioning vs Nexalis |
|---|---|---|---|---|
IRX-211 (BTcP) | Fentanyl buccal tablet (Fentora) | Teva | Approved | Entrenched rapid-onset opioid standard; dependency/abuse concerns are Nexalis' wedge |
IRX-211 | Fentanyl sublingual (Abstral) | Various licensees | Approved | Same |
IRX-211 | Intranasal fentanyl (Instanyl / PecFent) | Various | Approved | Fastest-onset opioid alternative |
IRX-211 | Oral dronabinol (Marinol, Syndros) | Various | Approved (other indications) | Same molecule, slow oral onset; provides 505(b)(2) reference safety data |
IRX-616a (PD) | Benzodiazepines (alprazolam, clonazepam) | Pfizer/Viatris, generics | Approved | Cheap generic standard; dependency concerns |
IRX-616a | SSRIs/SNRIs | Generics | Approved | Maintenance therapy, slow onset; not acute |
IRX-616a | Epidiolex (oral CBD) | Jazz Pharmaceuticals | Approved (epilepsy) | Oral CBD reference; not indicated for PD |
SRX-25 (TRD) | Spravato (intranasal esketamine) | Johnson & Johnson | Approved | Market leader; requires supervised clinic dosing (Nexalis' wedge) |
SRX-25 | Auvelity (dextromethorphan-bupropion) | Axsome | Approved (MDD) | Oral NMDA-modulating competitor |
SRX-25 | Psilocybin (COMP360) | Compass Pathways | Phase 3 | Novel TRD entrant |
SRX-25 | GH001 (inhaled mebufotenin) | GH Research | Clinical | Inhaled rapid-acting TRD candidate |
ASX cannabinoid/mental-health peers | Zelira Therapeutics, Emyria, Bod Science, Avecho Biotechnology, Incannex Healthcare (now Nasdaq) | Various | Clinical/commercial | Compete for the same small-cap investor pool and partners |
Peer Comparison FY2025
| Metric | Nexalis (FY2025) | J&J Spravato franchise | ASX cannabinoid peers |
|---|---|---|---|
Revenue | A$0 | Approx. US$1.1bn (J&J FY2024 reporting; verify) | Mostly sub-A$5M; not compiled |
Revenue growth | — | Strong double-digit (verify) | Not compiled |
Net margin | — | Not disclosed at product level | Mostly loss-making |
R&D intensity | n.m. (R&D approx. 71% of opex) | — | Not compiled |



